


Express Mail No.: EM 293952038 US
Date of Deposit: April 6, 2009

Attorney Docket No.: 24024-506 CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled, et al.
SERIAL NUMBER: 10/767,064 EXAMINER : Anoop Kumar Singh
FILING DATE: January 29, 2004 ART UNIT : 1632
FOR: EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL
POPULATIONS IN MONONUCLEAR CELL CULTURES

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1 Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: C327-C335; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24024-506 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Date: April 6, 2009

for: Danaher, Reg. No. 63,993
Ivor R. Elrifi, Reg. No. 39,529
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled, et al.
SERIAL NUMBER: 10/767,064 EXAMINER : Anoop Kumar Singh
FILING DATE: January 29, 2004 ART UNIT : 1632
FOR: EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL
POPULATIONS IN MONONUCLEAR CELL CULTURES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1 Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: C327-C335; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24024-506 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Date: April 6, 2009

for: Danaher, Reg. No. 63,993
Ivor R. Elrifi, Reg. No. 39,529
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241



Express Mail Label No.: EM 293952038 US
Date of Deposit: April 6, 2009

Attorney Docket No.: 24024-506 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled, et al.
SERIAL NUMBER: 10/767,064 EXAMINER : Anoop Kumar Singh
FILING DATE: January 29, 2004 ART UNIT : 1632
FOR: EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL
POPULATIONS IN MONONUCLEAR CELL CULTURES

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Published Application A158 is not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Peled et al.
U.S.S.N.: 10/767,064

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-506 CON.

Respectfully submitted,

Date: April 6, 2009

for: Daniel W. Clark, Reg. No. 63,993
Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

4583871v.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled, et al.
SERIAL NUMBER: 10/767,064 **EXAMINER :** Anoop Kumar Singh
FILING DATE: January 29, 2004 **ART UNIT :** 1632
FOR: EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL
POPULATIONS IN MONONUCLEAR CELL CULTURES

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Published Application A158 is not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Peled et al.
U.S.S.N.: 10/767,064

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-506 CON.

Respectfully submitted,

Date: April 6, 2009

for: Daniel W. Clark, Reg. No. 63,993
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

4583871v.1